Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say ↗

January 30, 2026

As per the letter published by the FDA, the agency had alerted the company regarding its concerns for Relacorilant before.

Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology

What's going on in today's after hours session ↗

January 29, 2026

Via Chartmill

January 28, 2026

As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused...

Via Finterra

Topics Economy Intellectual Property

Corcept Therapeutics Inc (NASDAQ:CORT) Fits the Affordable Growth Profile ↗

January 23, 2026

Via Chartmill

Why Is CORT Stock Falling Today? ↗

December 31, 2025

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

2 Stocks Under $50 to Target This Week and 1 We Turn Down

January 26, 2026

In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.

Why Did Corcept Therapeutics Stock Surge Over 14% Today? ↗

January 22, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 22, 2026

Via Chartmill

1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 Facing Headwinds

January 21, 2026

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

1 Safe-and-Steady Stock to Target This Week and 2 That Underwhelm

January 19, 2026

Focused on therapies for endocrine and oncologic conditions, this biotech reported significant insider selling in its latest SEC filing.

Corcept Insider Transaction Explained After Shares Tumble 50% in One Day ↗

January 11, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 17.2% over...

Topics Regulatory Compliance

1 Healthcare Stock to Target This Week and 2 We Turn Down

January 05, 2026

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.5% in the morning session after the company’s stock faced continued selling pressure following the U.S. Food and Drug...

Topics Stocks

Why Corcept (CORT) Stock Is Trading Lower Today

January 05, 2026

Nasdaq, S&P 500 Futures Point To Strong New-Year Open On Wall Street: Why TSLA, BIDU, SLV, STLA Are On Traders' Radar Today ↗

In today's session, these stocks are experiencing unusual volume. ↗

January 02, 2026

Via Chartmill

January 02, 2026

Check out the companies making headlines yesterday:

Topics Stocks

Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio

January 01, 2026

One of the company's key drugs won't be challenged by a competing medication anytime soon.

Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗

December 31, 2025

The final day of 2025 saw the company get a sharp "no" from a top regulator.

Why Corcept Therapeutics Plummeted by 50% Today ↗

December 31, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 51.4% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting...

Why Corcept (CORT) Shares Are Falling Today

December 31, 2025

Top movers analysis in the middle of the day on 2025-12-31: top gainers and losers in today's session. ↗

Here are the top movers in Wednesday's session. ↗

December 31, 2025

Via Chartmill

December 31, 2025

Via Chartmill

The market is filled with gapping stocks in Wednesday's session. ↗

December 31, 2025

Via Chartmill

3 Cash-Producing Stocks with Questionable Fundamentals

December 28, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.7% in the afternoon session after investor anxiety mounted ahead of a key U.S. Food and Drug Administration (FDA) decision for its...

Why Corcept (CORT) Stock Is Trading Lower Today

December 23, 2025

Corcept has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.8% to $81.75 per share while the index has gained 13.9%.

Topics Artificial Intelligence

Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings?

December 16, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.2% in the afternoon session after investment bank UBS initiated coverage of the company with a Neutral rating.

Topics Stocks

Why Corcept (CORT) Stock Is Down Today

December 16, 2025

Corcept (CORT) Q3 2025 Earnings Call Transcript

Topics Artificial Intelligence Economy Supply Chain

Corcept (CORT) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Corcept Therapeutics Inc (NASDAQ:CORT) Presents a Strong Growth and Technical Breakout Case ↗

Topics Earnings Intellectual Property

November 22, 2025

Corcept Therapeutics (CORT) combines strong fundamentals, including robust revenue growth and a healthy balance sheet, with a positive technical breakout setup.

Via Chartmill

Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.